A first-of-its-kind drug targeting a fused gene found in many types of cancer was effective in 93 percent of pediatric patients tested, researchers at UT Southwestern’s Simmons Cancer Center announced.
Most cancer drugs are targeted to specific organs or locations in the body. Larotrectinib is the first cancer drug to receive FDA breakthrough therapy designation for patients with a specific fusion of two genes in the cancer cell, no matter what cancer type. The research appears in The Lancet Oncology.
“In some cancers, a part of the TRK gene has become attached to another gene, which is called a fusion. When this occurs, it leads to the TRK gene being turned on when it’s not supposed to be and that causes the cells to grow uncontrollably. What’s unique about the drug is it is very selective; it only blocks TRKreceptors,” said lead author Dr. Ted Laetsch, Assistant Professor of Pediatrics and with the Harold C. Simmons Comprehensive Cancer Center.
Larotrectinib, targets TRK fusions, which can occur in many types of cancer. While the TRK fusions occur in only a small percentage of common adult cancers, they occur frequently in some rare pediatric cancers, such as infantile fibrosarcoma, cellular congenital mesoblastic nephroma, and papillary thyroid cancer, said Dr. Laetsch, who leads the Experimental Therapeutics Program (ETP) in the Pauline Allen Gill Center for Cancer and Blood Disorders at Children’s Health in Dallas.
“Every patient with a TRK fusion-positive solid tumor treated on this study had their tumor shrink. The nearly universal response rate seen with larotrectinib is unprecedented,” Dr. Laetsch said.
Among them was 13-year-old Briana Ayala of El Paso, who aspires to a career in fashion design. In 2016, Briana was found to have a rare tumor in her abdomen wrapped around her aorta, the largest artery in the body.
Surgeons in her hometown said it would be too dangerous to operate, so her family brought Briana to Children’s Health in Dallas, where UT Southwestern Professor of Surgery Dr. Stephen Megison had to remove portions of her aorta while removing most of the tumor.
But the cancer started to grow again and no further treatments were available.
Dr. Laetsch sent her tumor for genetic testing and found that Briana’s cancer had the TRK fusion, meaning the new drug might help.
Briana enrolled in the phase 1 clinical trial of larotrectinib and began taking the drug twice a day. Within weeks her pain and the swelling in her abdomen diminished, and scans showed her tumors had shrunk significantly.
Nearly two years later, Briana is back in school and playing with her dog, Goofy, and the family’s seven parakeets. She’s also been able to pick up her sketch pad and her dreams of a New York City fashion career.
“These are the kind of amazing responses we’ve seen with larotrectinib,” said Dr. Laetsch, “and this is why I’m so excited about it.”
The results of the larotrectinib trial in adult patients – a 75 percent response rate – were published last month in the New England Journal of Medicine.
The TRK-fusion mutation can be present in many types of cancers, including lung, colon, thyroid, and breast cancer, as well as certain pediatric tumors. TRK, short for tropomyosin receptor kinase, is a gene that plays a key role in brain and nervous system development and has a limited role in nervous system functions such as regulating pain in later life.
Larotrectinib belongs to a class of molecules known as kinase inhibitors, which work by cutting back on the enzymatic activity of a key cellular reaction. The selectivity of the drug means it does not cause the severe side effects associated with many traditional cancer treatments, and none of the patients with TRK fusions had to quit the study because of a drug-induced side effect.
Equally important, the response was long-lasting for most patients. “For some of the targeted drugs in the past, many patients responded initially, but then resistance developed quickly. To date, the response to this drug seems to be durable in most patients,” said Dr. Laetsch, who investigates the use of tumor molecular profiling to guide therapy in UT Southwestern’s Pediatric Hematology and Oncology Division.
A next step in the research is a clinical trial involving a similar drug for those patients who developed resistance. Dr. Laetsch will be the national leader for that clinical trial in children.
The Latest on: Larotrectinib
via Google News
The Latest on: Larotrectinib
- Drug is 'Game Changer'; Screen Cancer Patients For TRK Fusion on December 11, 2018 at 10:54 am
The novel drug larotrectinib (Vitrakvi, Bayer/Loxo Oncology) that was approved recently by the Food and Drug Administration is a precision model "game changer," say clinical trial investigators. The d... […]
- FDA Approves New Cancer Drugs from Pfizer and Loxo Oncology on December 10, 2018 at 4:18 am
“The FDA approval of larotrectinib marks an important milestone in how we treat cancers that have an NTRK gene fusion—a rare driver of cancer. I have seen firsthand how treatment with larotrectinib, w... […]
- Health ministry clarifies on drug for cancer treatment on December 7, 2018 at 2:43 pm
The Ministry of Public Health’s Pharmacy and Drug Control Department has issued a clarification regarding the drug Larotrectinib, commercially known as Vitrakvi for the treatment of some types of canc... […]
- FDA approves new drug reflecting cutting-edge, 'tissue-agnostic' effort to beat cancer on November 28, 2018 at 6:29 am
The approval this week for Vitrakvi, the brand name for larotrectinib, marks an emerging method for developing cancer drugs that are “tissue agnostic” – drugs that are not specific to one organ such a... […]
- Vitrakvi approved for cancers with specific genetic biomarker on November 27, 2018 at 7:38 pm
TUESDAY, Nov. 27, 2018 -- Vitrakvi, or larotrectinib, has been approved by the U.S. Food and Drug Administration to treat cancers with a specific inherited trait called a biomarker. The approval marks ... […]
- UCLA health expert available to comment on FDA approval of targeted cancer therapy, larotrectinib, for patients with a wide variety of cancers. on November 26, 2018 at 11:48 pm
UCLA pediatric oncologist Dr. Noah Federman, director of the UCLA Jonsson Comprehensive Cancer Center’s Pediatric Bone and Soft Tissue Sarcoma Program and medical director of the UCLA CTSI’s Clinical ... […]
- FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2) on November 26, 2018 at 11:34 pm
- First treatment with a tumor-agnostic indication at the time of initial FDA approval - 75% overall response rate (ORR) (95% CI, 61%, 85%) [22% complete response (CR) and 53% partial response (PR)] a... […]
- German stocks - Factors to watch on Nov. 27 on November 26, 2018 at 10:12 pm
Larotrectinib, a drug owned by Bayer’s U.S. partner Loxo Oncology Inc. shown to be effective against a wide variety of cancers won U.S. approval on Monday, according to the Food and Drug Administratio... […]
- FDA Approves Vitrakvi® (larotrectinib), the First Ever TRK Inhibitor, for Patients with Advanced Solid Tumors Harboring an NTRK Gene Fusion(1,2) on November 26, 2018 at 5:49 pm
- 75% overall response rate (ORR) (95% CI, 61%, 85%) [22% complete response (CR) and 53% partial response (PR)] across various solid tumors in adults and children (N=55)(2) - Adverse events (AE) of an... […]
via Bing News